Publication | Closed Access
Management of Paediatric Patients With Medically Refractory Crohn’s Disease Using Ustekinumab: A Multi-Centred Cohort Study
62
Citations
22
References
2018
Year
Subcutaneous UST should be considered a viable therapeutic option for paediatric patients who are refractory to other biological agents. Prospective randomised trials are needed.
| Year | Citations | |
|---|---|---|
Page 1
Page 1